// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























959 Abstracts

Combining anti-androgen therapy and PARP inhibition results in synergistic cytotoxicity of metastatic castration-resistant prostate cancer (mCRPC) cells

Sahithi Pamarthy - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Neutralization of IGF-I and -II ligands with the fully humanized bispecific monoclonal antibody xentuzumab inhibits AR-V7-induced enzalutamide resistance in castration-resistant prostate cancer

Gang Liu - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

A novel approach for targeting androgen receptor signaling axis in prostate cancer

Salma Kaochar - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

CB-7598

Bromodomain and extra-terminal motif protein inhibitors (BETi) in metastatic castration resistant prostate cancer (mCRPC): A novel mechanism for regulating androgen receptor variant 7 (ARV7)

Jonathan Welti - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Rb1 suppresses prostate cancer metastasis and lineage plasticity underlying castration resistance

Sheng-Yu Ku - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Regulation of androgen signaling axis and tumor suppressive function of miR-149-5p in prostate cancer

Savita Singh - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients

Ada Gjyrezi - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Clinical and genomic resistance to second generation androgen blockade in paired biopsies of metastatic castration-resistant prostate cancer

G. Celine Han - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Activation of AR signaling by mifepristone enhances prostate cancer growth and impairs enzalutamide response

Haiying Zhou - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer: a pilot multidisciplinary study

Jingsong Zhang - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

An oral Androgen Receptor PROTAC degrader for prostate cancer

Taavi K. Neklesa - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Characterization of molecular mechanisms of cytoplasmic trafficking and nuclear translocation of AR splice variants ARv7

Eiman Mukhtar - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Metformin enhances the anti-prostate cancer activity of abiraterone and enzalutamide

Yi Xie - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Potential role of androgen receptor in aromatase inhibitor resistance

Caleb Hunt - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

CB-7598

Identifying a predictive biomarker for chemotherapy (taxane) in patients with metastatic castration resistance prostate cancer

Greg A. Rothchild - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Redirecting abiraterone metabolism to biochemically fine tune prostate cancer therapy

zhenfei li - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Tumor suppressing dual-action miRNA: Targeting Warburg effect and androgen receptor function in CRPC

Jey Sabith Ebron - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

FOXA1, a novel regulator of neuroendocrine differentiation

Jung Kim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Androgen receptor activity is reprogrammed by lysine-specific demethylase 1 in prostate cancer

Shuai Gao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Assays for androgen receptor activity using cell based ARE reporter systems

Waqas Azeem - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Copyright © 2026. QuantiNova All rights reserved